Drugs Containing Excipient (Inactive Ingredient) 1,1,1,2-TETRACHLOROETHANE

« Back to Dashboard

Generic drugs containing 1,1,1,2-TETRACHLOROETHANE excipient

Company	Ingredient	NDC	Excipient
Armstrong Pharmaceuticals Inc	ipratropium bromide inhalation	17270-0401	1,1,1,2-TETRACHLOROETHANE

1,1,1,2-Tetrachloroethane Market Dynamics, Pharmaceutical Status, and Financial Trajectory

Last updated: October 24, 2026

1,1,1,2-Tetrachloroethane is not an established pharmaceutical excipient. The substance, also known as 1,1,1,2-tetrachloroethane and identified by CAS Registry Number 630-20-6, is a chlorinated solvent with limited industrial relevance and significant toxicological and regulatory constraints. No identifiable commercial pharmaceutical-excipient market, FDA-approved drug product base, Orange Book patent estate, or generic-entry cycle exists for this substance.

The most likely financial trajectory is continued contraction or specialized non-pharmaceutical use rather than growth. Public market reports generally aggregate chlorinated solvents and do not isolate 1,1,1,2-tetrachloroethane as a reportable product category.

Is 1,1,1,2-tetrachloroethane an approved pharmaceutical excipient?

No established pharmaceutical-excipient status has been identified for 1,1,1,2-tetrachloroethane.

The substance is not recognized as a mainstream excipient in the FDA Inactive Ingredient Database, and it does not have a recognized USP-NF excipient monograph comparable to ethanol, acetone, propylene glycol, polyethylene glycol, or ethyl acetate. Its toxicological profile makes routine use in oral, injectable, ophthalmic, inhaled, or topical drug products commercially and regulatorily impractical.

Attribute	1,1,1,2-Tetrachloroethane
CAS number	630-20-6
Molecular formula	C2H2Cl4
Substance class	Chlorinated aliphatic solvent
Pharmaceutical excipient status	No established mainstream status
FDA inactive-ingredient position	No established approved-use profile identified
USP-NF monograph	No recognized excipient monograph identified
Orange Book relevance	None identified
Primary commercial relevance	Specialty solvent and chemical intermediate use
Main commercial constraint	Toxicity, worker exposure, waste handling, and substitution

The compound should not be confused with 1,1,1-trichloroethane, a different substance historically used as an industrial solvent, or 1,1,2,2-tetrachloroethane, the more commonly discussed tetrachloroethane isomer.

What are the chemical and toxicological characteristics of 1,1,1,2-tetrachloroethane?

1,1,1,2-Tetrachloroethane is a volatile chlorinated organic compound. Public chemical databases classify it as a hazardous substance with risks associated with inhalation, skin contact, and repeated exposure. Toxicological concerns include central nervous system effects, liver toxicity, and other systemic effects reported for highly chlorinated ethanes.

The substance’s risk profile creates several barriers to pharmaceutical use:

• Low tolerance for residual-solvent exposure.
• Difficult justification for use in patient-contact products.
• Occupational exposure-control requirements.
• Hazardous-waste treatment and disposal costs.
• Pressure from regulators and customers to replace chlorinated solvents.
• Limited compatibility with modern “green chemistry” procurement standards.

The International Council for Harmonisation residual-solvent framework places tight controls on solvents with significant toxicological concerns. Even where a solvent is not expressly listed in a finished-product standard, drug manufacturers must establish safety, control residual levels, and demonstrate that the process is suitable for its intended use (ICH, 2021).

What is the market size for 1,1,1,2-tetrachloroethane?

No reliable standalone market-size estimate is available for 1,1,1,2-tetrachloroethane. Commercial datasets generally group the substance with broader categories such as chlorinated solvents, halogenated chemicals, or specialty industrial solvents.

A defensible market assessment is therefore qualitative:

Market indicator	Assessment
Standalone pharmaceutical-excipient market	Effectively absent
Branded pharmaceutical products	None identified
API manufacturing demand	Limited and not publicly quantified
Contract-manufacturing demand	Limited and project-specific
Commodity-scale demand	Unlikely
Pricing transparency	Low
Public company revenue disclosure	Not separately reported
Growth outlook	Flat to declining
Substitution risk	High

The absence of a standalone market estimate is itself commercially significant. A supplier cannot reliably build a pharmaceutical-excipient revenue forecast from public drug-development pipelines, FDA product approvals, or pharmaceutical procurement data.

How does the financial trajectory compare with other pharmaceutical solvents?

1,1,1,2-Tetrachloroethane has a materially weaker financial position than solvents commonly used in pharmaceutical development and manufacturing.

Solvent	Pharmaceutical relevance	Regulatory and commercial position
Ethanol	High	Broadly accepted, large supply base
Acetone	High	Common process and cleaning solvent
Ethyl acetate	High	Widely used and comparatively favorable
Isopropanol	High	Established in manufacturing and sanitation
Propylene glycol	High	Excipient and solvent applications
Dichloromethane	Moderate	Used in some processes but subject to safety controls
Chloroform	Low	Strong toxicity and regulatory limitations
1,1,1,2-Tetrachloroethane	Very low	Limited use and high substitution pressure

The economic advantage of established alternatives comes from scale, qualification history, validated analytical methods, and broad supplier networks. A pharmaceutical manufacturer would generally need a compelling process-performance reason to select 1,1,1,2-tetrachloroethane over more widely accepted solvents.

What regulatory barriers affect pharmaceutical use?

FDA regulatory status

There is no established FDA drug-product market based on 1,1,1,2-tetrachloroethane as an excipient. The FDA Inactive Ingredient Database is the primary reference for inactive ingredients that have appeared in approved drug products, but database inclusion would not itself establish unrestricted approval for all routes, doses, or formulations (U.S. Food and Drug Administration, n.d.-a).

A new drug product using the substance would face requirements involving:

1. Identity and purity specifications.
2. Residual-solvent controls.
3. Toxicological justification.
4. Route-specific exposure assessment.
5. Manufacturing controls.
6. Stability and compatibility data.
7. Justification for why safer alternatives are unsuitable.

For a conventional generic drug, introduction of a nonstandard and toxic excipient could create formulation and regulatory complications without offering a clear commercial benefit.

Environmental and workplace regulation

The substance is subject to chemical-inventory and hazard-communication regimes in major jurisdictions. European regulatory treatment under REACH and classification under the EU Classification, Labelling and Packaging framework can affect manufacture, import, downstream use, packaging, and workplace handling (European Chemicals Agency, n.d.).

In the United States, use and distribution are affected by Toxic Substances Control Act requirements, occupational exposure rules, hazardous-waste requirements, and state-level chemical controls. Regulatory obligations increase the total cost of ownership beyond the purchase price.

Pharmaceutical quality systems

A pharmaceutical manufacturer would need supplier qualification, impurity profiling, validated removal methods, residual testing, and change-control procedures. These costs would be disproportionate for a solvent with no established excipient platform.

What patents protect 1,1,1,2-tetrachloroethane?

No material active pharmaceutical patent estate has been identified for 1,1,1,2-tetrachloroethane.

The molecule is an old, low-complexity chemical. Any basic composition-of-matter or early process patents would generally be expected to have expired. Modern patent activity, if present, would more likely concern:

• Manufacture of chlorinated ethanes.
• Purification methods.
• Recovery and recycling.
• Specialty industrial formulations.
• Chemical conversion into other intermediates.
• Waste treatment or emissions control.

These rights would not create pharmaceutical-excipient exclusivity.

Patent category	Commercial relevance
Composition of matter	No practical current exclusivity expected
Pharmaceutical formulation	None identified
Method of treatment	Not applicable
Drug-delivery system	None identified
API manufacturing	Potentially relevant only to chemical suppliers
Solvent recovery	Possible industrial relevance
Environmental remediation	Possible but not a product-market barrier

Does 1,1,1,2-tetrachloroethane have Orange Book listings or Paragraph IV risk?

No Orange Book listing or Paragraph IV litigation risk has been identified.

The Orange Book concerns approved drug products and associated patents or regulatory exclusivities. Because 1,1,1,2-tetrachloroethane is not an active pharmaceutical ingredient or established drug-product excipient, it does not generate a conventional Orange Book patent challenge pathway (U.S. Food and Drug Administration, n.d.-b).

The following pharmaceutical exclusivity mechanisms are therefore not materially applicable:

• New chemical entity exclusivity.
• Hatch-Waxman Paragraph IV litigation.
• Pediatric exclusivity.
• Orphan-drug exclusivity.
• New formulation exclusivity.
• Method-of-use listing in the Orange Book.

Any patent dispute involving the substance would more likely be an industrial-chemical or environmental matter rather than a generic-drug dispute.

What companies are challenging or commercializing the substance?

No significant pharmaceutical company, generic-drug manufacturer, or excipient specialist is publicly associated with commercializing 1,1,1,2-tetrachloroethane as a drug excipient.

Potential suppliers would most likely be specialty chemical distributors, custom manufacturers, or legacy chlorinated-solvent producers. Their exposure would depend on industrial customers, not drug-product volume. Supplier concentration, production geography, and sales are difficult to quantify because the substance is rarely disclosed as a standalone revenue category.

The commercial landscape is therefore fragmented and low-transparency:

• No dominant pharmaceutical-grade brand.
• No visible excipient consortium.
• No major drug-development pipeline.
• No established compendial-grade premium.
• No identifiable licensing market.
• No meaningful biosimilar or generic-drug demand driver.

What generic launch risks exist?

Generic-launch risk is not the relevant commercial framework because there is no established reference drug product dependent on this substance.

The more relevant risks are:

1. Formulation substitution: manufacturers replace the solvent with ethanol, acetone, ethyl acetate, or another validated alternative.
2. Regulatory rejection: authorities require extensive justification for patient exposure.
3. Supplier discontinuation: low-volume production becomes uneconomic.
4. Qualification failure: pharmaceutical customers reject the material because of impurity or toxicology concerns.
5. Cost escalation: hazardous handling and disposal increase delivered cost.
6. Geographic restrictions: local regulations limit manufacture, import, or use.

A supplier relying on pharmaceutical demand would face a high probability of demand erosion rather than a conventional patent-cliff event.

How strong is the commercial position of 1,1,1,2-tetrachloroethane?

Its commercial position is weak in pharmaceuticals and dependent on niche industrial applications.

Commercial factor	Rating
Pharmaceutical demand	Very weak
Regulatory defensibility	Weak
Switching costs	Low to moderate
Supplier differentiation	Limited
Patent protection	Weak or absent
Substitution threat	High
Pricing power	Low
Long-term volume outlook	Declining or uncertain
Investment case	Unattractive without captive industrial demand

The substance could retain value where it has specialized solvency, reaction, or separation properties and where substitution would require expensive process redevelopment. That value would be process-specific, not derived from pharmaceutical exclusivity.

What is the financial outlook through the end of the decade?

The base case is a small, declining specialty-chemical market with no identifiable pharmaceutical growth engine.

Scenario	Market outcome	Financial implication
Base case	Continued niche industrial use	Flat to declining revenue
Downside case	Accelerated substitution and regulatory tightening	Volume loss and plant-exit risk
Limited upside case	Captive use in a specialized chemical process	Stable project-based demand
Pharmaceutical case	No meaningful adoption	No material revenue contribution

A company evaluating investment, licensing, or manufacturing capacity should treat 1,1,1,2-tetrachloroethane as a hazardous specialty chemical, not as a pharmaceutical excipient platform. Valuation should be based on verified industrial contracts, production economics, regulatory liabilities, and replacement-cost analysis. It should not rely on pharmaceutical market multiples, excipient growth forecasts, or drug-pipeline assumptions.

Key Takeaways

• 1,1,1,2-tetrachloroethane is not an established pharmaceutical excipient.
• No material FDA-approved drug-product base, Orange Book listing, or Paragraph IV pathway has been identified.
• No meaningful pharmaceutical patent estate or formulation exclusivity is apparent.
• Public data does not support a standalone market-size estimate.
• The molecule faces high toxicity, compliance, disposal, and substitution pressures.
• Financial prospects are tied to niche industrial use rather than pharmaceutical demand.
• The base-case outlook is flat to declining revenue, with limited pricing power and high replacement risk.

Frequently Asked Questions

Is 1,1,1,2-tetrachloroethane used in tablet manufacturing?

No established tablet-manufacturing use has been identified. Common tablet solvents and processing liquids include ethanol, water, acetone, isopropanol, and ethyl acetate, depending on the formulation and process.

Is 1,1,1,2-tetrachloroethane listed in the FDA Inactive Ingredient Database?

No established approved-use profile has been identified in the FDA Inactive Ingredient Database. Absence from the database does not independently prohibit all use, but it indicates the lack of a recognized history in approved drug products.

Is 1,1,1,2-tetrachloroethane covered by USP standards?

No recognized USP-NF excipient monograph has been identified for this substance. It should not be treated as compendial pharmaceutical grade without a separate, product-specific qualification package.

Can a pharmaceutical company patent a formulation containing 1,1,1,2-tetrachloroethane?

A formulation patent could theoretically be pursued if it satisfied novelty, non-obviousness, and utility requirements. Such a patent would not establish regulatory acceptability and would face a weak commercial rationale if safer substitute solvents were available.

Is 1,1,1,2-tetrachloroethane a candidate for biosimilar manufacturing?

No. Biosimilar manufacturing depends on biologic active substances, cell-culture processes, purification systems, and formulation components. 1,1,1,2-tetrachloroethane has no recognized role in the biosimilar market.

References

1. European Chemicals Agency. (n.d.). 1,1,1,2-Tetrachloroethane: Substance information. https://echa.europa.eu/

2. International Council for Harmonisation. (2021). Q3C(R8): Impurities: Guideline for residual solvents. https://www.ich.org/

3. National Center for Biotechnology Information. (n.d.). PubChem compound summary: 1,1,1,2-Tetrachloroethane. https://pubchem.ncbi.nlm.nih.gov/

4. U.S. Food and Drug Administration. (n.d.-a). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/

5. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/